Followers | 0 |
Posts | 2177 |
Boards Moderated | 0 |
Alias Born | 04/13/2018 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, May 07, 2021 1:23:10 PM
Let's review what we know about Nader:
Nader is a pathological liar.
Nader is a habitual law breaker.
Nader is equally incompetent as he is narcissistic.
So we have that. Now let's review the drug itself.
1. Receptor Occupancy is at issue.
2. 700mg data which we supposedly have has mysteriously not been filed.
3. No trial to date has successfully shown that the drug actually works or should be approved.
But let's dig deeper into the company's playbook when it comes to accomplishing goals and seeking revenue.
1. Anytime a project nears completion or requires a formal approval. CYDY switches to another project further back of any other.
2. HIV the closest to any study in terms of approval and generating revenue has no timeline assigned and no further substantive updates from management. Literally the life line of the company is no where insight.
3. The COVID studies have all failed, and require new trials per Nader. These trials however are now being conducted mostly outside of the United States away from the eyes of a major regulatory agency.
4. Nader and CYDY is attempting to contravene international law by trying to charge a fee for compassionate use. They are trying to get away with avoiding the laws regarding the commercial sales of unapproved drugs. So you will have a US company selling an unapproved drug.
Here is what happens when a drug gets sourced to another country and ends up magically showing up in the hands of US Customers:
https://www.fda.gov/news-events/press-announcements/fda-warns-canarx-selling-unapproved-misbranded-and-unsafe-imported-drugs-unsuspecting-americans
For additional information here is how the FDA follows and deals with unapproved drug sales.
https://www.fda.gov/media/71004/download
The last time any compassionate use drug was allowed to "charge a fee" was medical cannibus but that was through a special act of their congress:
https://www.congress.gov.ph/legisdocs/third_17/HBT6517.pdf
So again a case of Nader not doing his homework or outright lying. A simple Google search would have informed him that the regulatory issues surrounding this would require more than a phone call to their FDA.
Why do I think Nader is lying and knows better. Because he is tossing maybes around like M&Ms. The same kind of stock pumping statements like the forever infamous "conditional EUA." His backtracking on that on the last Conference Call should be a dead giveaway on how he came up with "It's not commercial sales, it's a fee." Think of him explaining that before prosecutors, congress or a major regulatory body.
Nader has to go he is taking the company into legally perilous waters and putting off revenue producing projects. The man is a menace.
Recent CYDY News
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • BLOZF • Jul 29, 2024 9:07 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM